In a disturbing development for millions of older Americans, the Centers for Medicare & Medicaid Services (CMS) has officially announced the termination of the Part D Premium Stabilization Demonstration program after 2026.

This volte-face will likely result in higher monthly premiums for beneficiaries enrolled in stand-alone prescription drug plans. Originally established to cushion the financial shock of the Inflation Reduction Act’s new out-of-pocket spending cap, the subsidy program successfully reduced average premiums by an estimated $26 in 2025 and $16 in 2026.

The Rationale Behind the Reversal

CMS Administrator Dr. Mehmet Oz defended the decision, castigating the subsidy as a bailout for Big Insurance. The agency argues that private insurers now possess sufficient experience under the redesigned Part D benefit to price their products without the $9.8 billion federal subvention.

Disproportionate Impact on Traditional Medicare

Health policy experts warn that the precipitous removal of this financial buffer will disproportionately affect enrollees in traditional Medicare. While Medicare Advantage plans can utilize federal rebate dollars to suppress premium costs, stand-alone Part D plans lack this flexibility, potentially widening the affordability gap.

Despite the impending premium hikes, critical patient protections remain intact. The statutory out-of-pocket cap on prescription drugs and the monthly limit on insulin costs will persist into 2027. Nevertheless, beneficiaries are strongly urged to meticulously review their Annual Notice of Change this autumn and utilize the Medicare Plan Finder during the open enrollment period to ameliorate potential financial strain.